Crescent Biopharma (CBIO) EPS (Basic) (2013 - 2026)
Crescent Biopharma (CBIO) posted quarterly EPS (Basic) of -$3.43 for Q2 2026, up 32.14% year-over-year from -$2.6 in Q2 2025, and up 68.47% quarter-over-quarter from -$10.89 in Q1 2026.
Crescent Biopharma (CBIO) EPS (Basic) (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported EPS (Basic) for 14 consecutive years, with -$3.43 the latest figure, recorded in Q2 2026.
- In Q2 2026, EPS (Basic) rose 32.14% year-over-year to -$3.43; the TTM figure through Jun 2026 stood at -$31.93 (down 165.28% YoY), while the FY2025 annual figure was -$21.96, up 62.64% from the prior year.
- EPS (Basic) grew to -$3.43 in Q2 2026 per CBIO's latest filing, from -$10.89 in the prior quarter.
- Across five years, EPS (Basic) topped out at -$3.43 in Q2 2026 and bottomed at -$28.0 in Q1 2022.
- Historically, EPS (Basic) has averaged -$14.86 across 5 years, with a median of -$14.78 in 2023.
- Annual changes were most pronounced in 2025 — EPS (Basic) jumped 78.19% — and 2026, when it plunged 199.85%.
- Crescent Biopharma's EPS (Basic) stood at -$19.5 in 2022, then increased by 26.5% to -$14.33 in 2023, then sank by 93.34% to -$27.71 in 2024, then surged by 53.46% to -$12.9 in 2025, then soared by 73.37% to -$3.43 in 2026.
- Business Quant data shows CBIO's EPS (Basic) at -$3.43 in Q2 2026, -$10.89 in Q1 2026, and -$12.9 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 7.59 |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -1.96 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.23 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -0.72 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.06 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.18 |
| 10 | Crescent Biopharma | 1.10 Bn | 933.02 Mn | - | -0.38 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.43 |
| Mar 31, 2026 | -10.89 |
| Dec 31, 2025 | -12.90 |
| Sep 30, 2025 | -5.32 |
| Jun 30, 2025 | -11.92 |
| Mar 31, 2025 | -3.56 |
| Dec 31, 2024 | -27.71 |
| Sep 30, 2024 | -15.24 |
| Jun 30, 2024 | -15.66 |
| Mar 31, 2024 | -16.66 |
| Dec 31, 2023 | -14.33 |
| Sep 30, 2023 | -14.30 |
| Jun 30, 2023 | -12.85 |
| Mar 31, 2023 | -17.17 |
| Dec 31, 2022 | -19.50 |
| Sep 30, 2022 | -16.26 |
| Jun 30, 2022 | -25.32 |
| Mar 31, 2022 | -28.00 |
| Dec 31, 2021 | -33.86 |
| Sep 30, 2021 | -33.61 |